724P A prospective phase II study of gemcitabine plus platinum in combination with bevacizumab for metastatic renal medullary and collecting duct carcinoma (GETUG-AFU 24, BEVABEL trial)

Thibault, Constance; Elaidi, R.T.; Fléchon, Aude; Albigès, Laurence; Joly, Charlotte; Barthélémy, Philippe; Goupil, Marine Gross; Chevreau, Christine; Joly, Florence; Rolland, Frédéric; Laguerre, Brigitte; Gravis, Gwénaëlle; Brihoum, Meryem; Timsit, M-O.; Pécuchet, Nicolas; Allory, Yves; Оудард, С.

doi:10.1016/j.annonc.2020.08.796

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, unlike most other types of non-clear cell histologies, collecting duct RCCs may respond to cytotoxic chemotherapy using platinum-based chemotherapy as reported in several case reports and trials [62][63][64][65][66]. A specific study, the BEVABEL trial, combining chemotherapy and anti-angiogenics (bevacizumab) was conducted, however this study produced negative results, validating platinumbased chemotherapy as the standard of care [67].…”

Section: Clinical Datamentioning

confidence: 83%

Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data

Barthélémy

Rioux‐Leclercq

Thibault

et al. 2021

Cancer Treatment Reviews

View full text Add to dashboard Cite

Non-clear cell renal cell carcinomas (nccRCC) represent a highly heterogeneous group of kidney tumors, consisting of the following subtypes: papillary carcinomas, chromophobe renal cell carcinoma, so-called unclassified carcinomas or aggressive uncommon carcinomas such as Bellini carcinoma, renal cell carcinoma (RCC) with ALK rearrangement or fumarate hydratase-deficient RCC. Although non-clear cell cancers account for only 15 to 30% of renal tumors, they are often misclassified and accurate diagnosis continues to be an issue in clinical practice. Current therapeutic strategy of metastatic nccRCC is based primarily on guidelines established for clear cell tumors, the most common subtype, however this approach remains poorly defined. To date, published clinical trials for all histological nccRCC subtypes have been collectively characterized into one group, in contrast to clear-cell RCC, and given the small numbers of cases, the interpretation of study results continues to be challenging. This review summarizes the available literature for each nccRCC subtype and highlights the lack of supportive evidence from prospective clinical trials and retrospective studies. Future trials should evaluate treatment approaches which focus on a specific histological subtype and progress in treating nccRCC will be contingent on understanding the unique biology of their individual histologies.

show abstract

Section: Clinical Datamentioning

confidence: 83%

Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data

Barthélémy

Rioux‐Leclercq

Thibault

et al. 2021

Cancer Treatment Reviews

View full text Add to dashboard Cite

show abstract

“…Another study reported that the triple combination of bevacizumab, gemcitabine, and platinum salt, prolonged progression-free survival (median: 15.1 months) and OS (median: 27.8 months) in five cases of mCDC ( 17 ). However, in a prospective phase II trial of metastatic renal medullary and mCDC, this triple combination strategy was associated with low response rates and severe toxicity ( 18 ).…”

Section: Discussionmentioning

confidence: 99%

Persistent Response to a Combination Treatment Featuring a Targeted Agent and an Immune Checkpoint Inhibitor in a Patient With Collecting Duct Renal Carcinoma: A Case Report and Literature Review

Zhou

Huang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Collecting duct carcinoma (CDC) is a rare and highly aggressive subtype of kidney cancer that is associated with a poor prognosis. At present, there is no effective treatment for CDC. Herein, we report a case of metastatic CDC treated with a combination of a tyrosine kinase inhibitor and an immune checkpoint inhibitor. A 67-year-old male was diagnosed with CDC with lung and bone metastasis. Pazopanib and camrelizumab were administered after cytoreductive nephrectomy. The patient achieved a partial response after one cycle of treatment; however, he then experienced serious drug-induced hepatic injury. Therefore, we discontinued camrelizumab and administered monotherapy with pazopanib. Three months later, the cancer had progressed and axitinib and sintilimab were administered. The patient achieved a partial response, accompanied by the complete disappearance of the metastatic lesion in the lung. The patient had an excellent physical status after 11 months. This is the first reported case of metastatic CDC successfully treated with a combination of a tyrosine kinase inhibitor and an immune checkpoint inhibitor. This form of combination treatment may be an effective option for treating metastatic CDC.

show abstract

“…A report of five patients with metastatic cdRCC treated with triple combination of bevacizumab, gemcitabine and platinum salt followed by maintenance therapy with bevacizumab showing an objective response rate of 60% ( 40 ). Based on these data, a phase II trial was conducted to evaluate the efficacy and safety of this combination in patients with metastatic medullary RCC and cdRCC ( 41 ). From 34 patients enrolled 26 were metastatic cdRCC.…”

Section: Treatmentmentioning

confidence: 99%

Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease

et al. 2022

View full text Add to dashboard Cite

Collecting duct renal cell carcinoma (cdRCC), which until recently was thought to arise from the collecting ducts of Bellini in the renal medulla, is a rare and aggressive type of non-clear renal cell carcinoma (ncRCC), accounting for 1% of all renal tumors and with nearly 50% of patients being diagnosed with Stage IV disease. The median overall survival in this setting is less than 12 months. Several regimens of chemotherapies had been used based on morphologic and cytogenetic similarities with urothelial cell carcinoma described previously, although the prognosis still remains poor. The use of targeted therapies also did not result in favorable outcomes. Recent works using NGS have highlighted genomic alterations in SETD2, CDKN2A, SMARCB1, and NF2. Moreover, transcriptomic studies have confirmed the differences between urothelial carcinoma and cdRCC, the possible true origin of this disease in the distal convoluted tubule (DCT), differentiating from other RCC (e.g., clear cell and papillary) that derive from the proximal convoluted tubule (PCT), and enrichment in immune cells that may harbor insights in novel treatment strategies with immunotherapy and target agents. In this review, we update the current aspects of the clinical, molecular characterization, and new targeted therapeutic options for Collecting duct carcinoma and highlight the future perspectives of treatment in this setting.

show abstract

724P A prospective phase II study of gemcitabine plus platinum in combination with bevacizumab for metastatic renal medullary and collecting duct carcinoma (GETUG-AFU 24, BEVABEL trial)

Cited by 6 publications

References 0 publications

Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data

Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data

Persistent Response to a Combination Treatment Featuring a Targeted Agent and an Immune Checkpoint Inhibitor in a Patient With Collecting Duct Renal Carcinoma: A Case Report and Literature Review

Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease

Contact Info

Product

Resources

About